80%Confidence
0Views
FDASource
2026-03-24Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validations highlights regulatory risks in the compounding pharmacy supply chain for weight loss drugs. This may increase FDA scrutiny on imported active pharmaceutical ingredients for GLP-1 agonists and create sourcing challenges.
Actionable: Audit supply chains for Semaglutide APIs and verify all suppliers have completed proper process validations before distribution.
AI Confidence: 80%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now